# Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

> **NCT02173691** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 584 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium inhalation powder capsules
- **DRUG:** Salmeterol inhalation aerosol
- **DRUG:** Placebo inhalation aerosol
- **DRUG:** Placebo inhalation powder capsules

## Key facts

- **NCT ID:** NCT02173691
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** 2000-05
- **Final completion:** —
- **Target enrollment:** 584 (ACTUAL)
- **Last updated:** 2014-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173691, "Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02173691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*